;

4.63 CHF

Opening hours: 09:00 - 17:20 (Central European Standard Time: 12/24/2024 5:17:49 PM)
Exchange open, closes in 2 minutes
3.00 CHF (3.00%)
-1.49 CHF (-1.49%)
-10.79 CHF (-10.79%)
-30.79 CHF (-30.79%)
22.81 CHF (22.81%)
-74.02 CHF (-74.02%)
-79.65 CHF (-79.65%)

About Molecular Partners AG

Market Capitalization 157.04M

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Headquarters (address)

Wagistrasse 14

Schlieren 8952

Switzerland

Phone41 44 755 77 00
Websitehttps://www.molecularpartners.com
Employees167
SectorHealthcare
IndustryBiotechnology
TickerMOLN
ExchangeSwiss Stock Exchange
CurrencyCHF
52 week range3.10 - 9.50
Market Capitalization157.04M
P/E trailing1.75
P/E forward-2.12
Price/Sale26.16
Price/Book1.02
Beta3.00
EPS-1.89
EPS Switzerland (ID:153, base:188) 28.46

CleverShares.com|
2024 ©

1.0.9119.29486